Real-time Estimate Tradegate 06:07:23 2024-03-28 am EDT 5-day change 1st Jan Change
14.3 EUR -0.56% Intraday chart for Evotec SE +7.34% -32.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tubulis Technologies announced that it has received ?128 million in funding from a group of investors CI
Evotec Grants Claris Ventures Portfolio Biotech Firms Access to Testing Platform MT
EVOTEC : Warburg Research maintains a Buy rating ZD
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
Evotec Unit, Advanced BioScience Expand Agreement to Develop Antibodies Against HIV MT
Evotec's US Unit Expands Collaboration vs HIV with Advanced BioScience Laboratories MT
EVOTEC : RBC remains its Buy rating ZD
Jefferies lowers target for Evotec to 28 Euro - 'Buy' DP
EVOTEC : Jefferies remains its Buy rating ZD
Global markets live: Crest Nicholson, Gilead, United Airlines, 3M Company, General Electric... Our Logo
EVOTEC : RBC gives a Buy rating ZD
Evotec Says Former CEO Failed to Disclose Stock Trades Over 3 Years MT
Evotec Reiterates Trading Regulations Compliance Amid Former CEO’s Late Stock Trades Disclosure MT
Evotec says it promptly reported share trades withheld by former CEO RE
Transcript : Evotec SE - Special Call
Evotec share price decline halted for the time being - upgrade helps DP
RBC raises Evotec to 'Outperform' - Target 18.60 Euro DP
EVOTEC : Upgraded to Buy by RBC ZD
EVOTEC : RBC remains Neutral ZD
EVOTEC : RBC gives a Neutral rating ZD
Evotec Collaborates With Crohn's & Colitis Foundation on Inflammatory Bowel Disease Therapies MT
Evotec SE and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies CI
Dpa-AFX Overview: COMPANIES from 08/01/2024 - 15:15 DP
Evotec Gets $25 Million Payment Under Neuroscience Partnership With Bristol Myers Squibb MT
Evotec receives milestone payment from partnership with BMS - share price gains DP
Chart Evotec SE
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women's health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
14.38 EUR
Average target price
23 EUR
Spread / Average Target
+60.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Evotec SE - Xetra
  4. News Evotec SE
  5. Evotec, Bristol Myers Squibb Expand Team-Up to Cover New Alzheimer's Treatment Approach